Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Diagnostear Technologies Inc C.DTR

Healthcare Diagnostics & Research
DiagnosTear Technologies Inc., an ophthalmic company, engages in developing and commercializing disruptive diagnostic solutions for eye diseases. It develops TeaRx Dry Eye, a CE-IVD approved test based on the TeaRx platform intended for the identification and monitoring of Dry Eye Syndrome (TeaR DES); TeaRx Red Eye for differential assessment of adenoviral conjunctivitis, herpetic keratitis... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (CSE:DTR)

DiagnosTear: A diagnostic technology stock at the forefront of ocular disease

Trevor Abes  2 hours ago

DiagnosTear Technologies Inc. - Confirmation of No Material Change

Newsfile 5 days ago

DiagnosTear Announces Clinical Study with AlyaTec to Advance Analytical Validation and FDA Submission Pathway of TeaRx(TM) Red Eye Diagnostic Test

Newsfile 12 days ago

DiagnosTear Technologies Announces Initiation of a Collaboration with LV Prasad Eye Institute for Advancing the Clinical Validation of TeaRx(TM) Red Eye Diagnostic Test

Newsfile November 26, 2025

DiagnosTear Technologies Inc. Announces Closing of Private Placement of Units

Newsfile November 18, 2025

DiagnosTear Technologies Inc. Announces Upsizing of Private Placement of Units

Newsfile October 24, 2025

DiagnosTear Announces Frankfurt Stock Exchange Listing and Corporate Awareness Agreement

Newsfile October 22, 2025

DiagnosTear Technologies Inc. Announces Private Placement of Units

TheNewsWire June 3, 2025

DiagnosTear Technologies Inc. Announces Results of AGM

TheNewsWire April 24, 2025
View More News ››

Opinion & Analysis (CSE:DTR)

No current opinion is available.
View More Opinion ››

Bullboard Posts (CSE:DTR)

What is the plan?

Assuming now that the holidays are over we are going to see some more information about this company's direction and plans. 
KaiPar07 - January 7, 2025

Medical Devices/Biotech

There seems to be some life in the startup medtech/biotech market again.These guys seems to be very close to generating some revenue so...
Elway07 - December 13, 2024
View more Bullboard ››

Graphite One Inc.

Graphite One Inc.

Graphite One Inc. operates as mineral exploration company in the United States. Its primary project is the Graphite Creek ...
View More »